Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells

European Journal of Haematology

Volumn 69, Issue 5-6, 2002, Pages 318-320

  Kotani, Ai ^a   Takahashi, Atsushi ^a   Koga, Hikari ^a   Morita, Rinpei ^a   Fukuyama, Hidenao ^a   Ichinohe, Tatsuo ^a   Ishikawa, Takayuki ^a   Hori, Toshiyuki ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Chronic graft vs. host disease; Myasthenia gravis; Mycophenolate mofetil; OX40

Indexed keywords

AZATHIOPRINE; CD134 ANTIGEN; CD4 ANTIGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PYRIDOSTIGMINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CATARACT; CEREBRAL BLINDNESS; DETERIORATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; LEUKOENCEPHALOPATHY; LYMPHOCYTE COUNT; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RASH; SEIZURE; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD27; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036867536     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.02789.x     Document Type: Article

References (12)

1. Smith CIE, Hammarstrm L, Lefvert AK. Bone marrow grafting induces acetylcholine receptor antibody formation. Lancet 1985;1:978.
2. Dowell JE, Moots PL, Stein RS. Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma. Bone Marrow Transplant 1999;24:1359-1361.
3. Koski SL, Mackey JR, Mackey DS. Myasthenia gravis post-allogeneic bone marrow transplantation revisited. Bone Marrow Transplant 1998;22:403-404.
4. Baron F, Sadzot B, Wang F, Beguin Y. Myasthenia gravis without chronic GVHD after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;22:197-199.
5. +) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3162-3164.
6. Mele TS, Halloran PF. The use of mycophenolate mofetilin transplant recipients. Immunopharmacology 2000;47:215-245.
7. Sherer Y, Shoenfelt Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 1998;22:873-881.
8. Kook H, Goldman F, Padley D, et al. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: Immunophenotypic analysis and factors affecting the speed of recovery. Blood 1996;88:1089-1097.
9. - cells in long-term survivors of graft-versus-host disease after allogeneic bone marrow transplantation. Jpn J Clin Oncol 1992;22:238-243.
10. Higaki Y, Yamada O, Okamura T, et al. Granzyme-B-containing lymphocyte involvement in epidermal injury in graft-versus-host disease. Dermatology 2001;202:94-98.
11. Hayashi M, Matsuda O, Ishida Y, Kida K. Change of immunological parameters in the clinical course of a myasthenia gravis patient with chronic graft-versus-host disease. Acta Paediatr Jpn 1996;38:151-155.
12. Ciafaloni E, Sanders DB. Advances in myasthenia gravis. Curr Neurol Neurosci Rep 2002;2:89-95.